Intra-abdominal infections: Considerations for the use of the carbapenems

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 2, 2007, Pages 167-182

  Kioumis, Ioannis P ^a,b   Kuti, Joseph L ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Carbapenems; Ertapenem; Imipenem; Intra abdominal infection; Meropenem; Peritonitis

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; BIAPENEM; CARBAPENEM DERIVATIVE; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CILASTATIN; CILASTATIN PLUS IMIPENEM; CLINDAMYCIN; ERTAPENEM; GENTAMICIN; IMIPENEM; MEROPENEM; METRONIDAZOLE; MOXIFLOXACIN; NETILMICIN; PANIPENEM; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIGECYCLINE; TOBRAMYCIN; UNINDEXED DRUG;

ABDOMINAL ABSCESS; ABDOMINAL INFECTION; ABDOMINAL SURGERY; ADJUVANT THERAPY; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; BACTERIAL PERITONITIS; CANDIDA ALBICANS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG STRUCTURE; DRUG USE; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; INTESTINE FLORA; KLEBSIELLA PNEUMONIAE; META ANALYSIS; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MORBIDITY; MORTALITY; MYCOBACTERIUM TUBERCULOSIS; NEISSERIA GONORRHOEAE; NEPHROTOXICITY; PATHOGENESIS; POSTOPERATIVE PERIOD; PREVALENCE; REVIEW; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; SYSTEMATIC REVIEW;

CARBAPENEMS; DRUG RESISTANCE, BACTERIAL; HUMANS; PERITONITIS;

EID: 33846840765     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.2.167     Document Type: Review

References (179)

1. TELLADO JM, WILSON SE: Empiric treatment of nosocomial intra abdominal infections: a focus on the carbapenems. Surg. Infect. (2005) 6:329-343.
2. VAN GOOR H: Interventional management of abdominal sepsis: when and how. Langenbeck's Arch. Surg. (2002) 387:191-200.
3. FARTHMAN EH, SCHOFFEL U: Principles and limitation of operative management of intra-abdominal infections. World J. Surg. (1990) 14:210-217.
4. CHEADLE WG, SPAIN DA: The continuing challenge of intra-abdominal infection. Am. J. Surg. (2003) 186(5A):15S-22S.
5. BARIE PS, HYDO LJ, EACHEMPATI SR: Longitudinal outcomes of intra-abdominal infection complicated by critical illness. Surg. Infect. (2004) 5(4):365-373.
6. CHRISTOU NV, BARIE PS, DELLINGER EP et al.: Surgical Infection Society Intra-abdominal Infection Study: prospective evaluation of management techniques and outcome. Arch. Surg. (1993) 128:193-198.
7. GRUNAU G, HEEMKEN R, HAU T: Predictors of outcome in patients with postoperative intra-abdominal infection. Eur. J. Surg. (1996) 162:619-625.
8. KOPERNA T, SCHULTZ F: Relaparotomy in peritonitis: prognosis and treatment of patients with persisting intra-abdominal infection. World J. Surg. (2000) 24:32-37.
9. MERLINO JI, MELANGONI MA, SMITH CM, LANGE RL: Prospective randomized trials affect the outcomes of intra-abdominal infection. Ann. Surg. (2001) 233:859-866.
10. BOHNEN JM, SOLOMKIN JS, DELLINGER EP et al.: Guidelines for clinical care: anti-infective agents for intra-abdominal infection. A Surgical Infection Society policy statement. Arch. Surg. (1992) 127:83-89.
11. SOLOMKIN JS, MAZUSKI JE, BARON EJ et al.: Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin. Infect. Dis. (2003) 37:997-1005.
12. CHEADLE WG, SPAIN DA: The continuing challenge of intra-abdominal infection. Am. J. Surg. (2003) 28:15S-22S.
13. SPECK WT, DRESDALE SS, MCMILLAN RW: Primary peritonitis and nephrotic syndrome. Am. J. Surg. (1974) 127:267-269.
14. NOHR CW, MARSHALL DG: Primary peritonitis in children. Can. J. Surg. (1984) 27:179-181.
15. MOWAT C, STANLEY AJ: Spontaneous bacterial peritonitis - diagnosis, treatment, and prevention. Aliment. Pharmacol. Ther. (2001) 15:1851-1859.
16. GOLDEN GT, SHAW A: Primary peritonitis. Surg. Gynecol. Obstet. (1972) 278:513-516.
17. WILCOX CM, DISMUKES WE: Spontaneous bacterial peritonitis: a review of pathogenesis, diagnosis and treatment. Medicine (1987) 66:447-456.
18. CONN HO: Spontaneous bacterial peritonitis in cirrhosis: variations on a theme. Medicine (1971) 50:161-197.
19. TARGAN SR, CHOW AW, GUSE LB: Role of anaerobic bacteria in spontaneous peritonitis of cirrhosis: report of two cases and review of the literature. Am. J. Med. (1977) 62:397-403.
20. CORREIA JP, CONN HO: Spontaneous peritonitis in cirrhosis: endemic or epidemic? Med Clin. North Am. (1975) 59:963-981.
21. BOHNEN J, BOULANGER M, MEAKINS JL, MCLEAN APH: Prognosis in generalized peritonitis. Relation to cause and risk factors. Arch. Surg. (1983) 118:285-290.
22. NICHOLS RL: Intra-abdominal infections: An overview. Rev. Infect. Dis (1985) 7(Suppl. 4):S709-S715.
23. GORBACH SL, NAHAS L, LERNER PI et al.: Studies in fecal microorganisms in man. Gastroenterology (1967) 53:845-855.
24. TALLY FP, MCGOWAN K, KELLUM JM et al.: A randomized comparison of cefoxitin with or without amikacin and clindamycin plus amikacin in surgical sepsis. Ann. Surg. (1981) 193:318-323.
25. ROTSTEIN OD, PRUETT TL, SIMMONS RL: Microbiologic features and treatment of persistent peritonitis in patients in the intensive care unit. Can. J. Surg. (1986) 29:247-250.
26. SIRINEK KR: Diagnosis and treatment of intra-abdominal abscesses. Surg. Infect. (2000) 1:31-38.
27. LEVISON ME, BUSH LM: Peritonitis and intraperitoneal abscesses. In: Principles and Practice of Infectious Diseases, 6th edn. Mandell GL, Bennett JE, Dolin R. Elsevier Churchill Livingstone (2005) Section F(68):927-951.
28. MARSHALL JC, INNES M: Intensive care unit management of intra-abdominal infection. Crit. Care Med. (2003) 31(8):2228-2237.
29. MARSHALL JC: Intra-abdominal infections. Microb Infect (2004) 6:1015-1025.
30. SITGES-SERRA A, LOPEZ MJ, GIRVENT M et al.: Postoperative enterococcal infection after treatment of complicated intra-abdominal sepsis. Br. J. Surg. (2002) 89:361-367.
31. BARIE PS, CHRISTOU NV, DELLINGER EP et al.: Pathogenicity of the enterococcus in surgical infections. Ann. Surg. (1990) 212:155-159.
32. RÖHRBORN A, WACHA H, SCHÖFFEL U et al.: Coverage of enterococci in community acquired secondary peritonitis: results of a randomised trial. Surg. Infect. (2000) 1:95-107.
33. NATHENS AB, ROTSTEIN OD, MARSHALL JC: Tertiary peritonitis: clinical features of a complex nosocomial infection. World J. Surg. (1998) 22:158-163.
34. NICHOLS RL, MUZIK AC: Enterococcal infections in surgical patients: the mystery continues. Clin. Infect. Dis. (1992) 15:72-76.
35. CALANDRA T, BILLE J, SCHNEIDER R et al.: Clinical significance of Candida isolated from peritoneum in surgical patients. Lancet (1989) 2:1437-1440.
36. SANDVEN P, QVIST H, SKOVLUND P et al.: Significance of Candida recovered from intra-operative specimens in patients with intra-abdominal perforations. Crit. Care Med. (2002) 30:1513-1519.
37. MONTRAVERS P, DUPONT H, GAUZIT R et al.: Candida as a risk factor for mortality in peritonitis. Crit. Care Med. (2006) 34:646-652.
38. ALTEMEIER WA: The pathogenicity of the bacteria of appendicitis peritonitis. Surgery (1942) 11:374-384.
39. NAMAVAR FA, VERWEIJ MJ, BAL M et al.: Effects of anaerobic bacteria on killing of Proteus mirabilis by human polymorphonuclear leucocytes. Infect. Immun. (1983) 40:930-935.
40. BROOK I: Anaerobic infections in childhood. Rev. Infect. Dis. (1984) 6(Suppl. 1):S187-S192.
41. ONDERDONK AB, WEINSTEIN WN, SULLIVAN NM et al.: Experimental intra-abdominal abscess in rats: quantitative bacteriology of infected animals. Infect. Immun. (1974) 10:1256-1259.
42. WEINSTEIN WM, ONDERDONK AB, BARTLETT JG et al.: Antimicrobial therapy of experimental intra-abdominal sepsis. J. Infect. Dis. (1975) 132:282-286.
43. ONDERDONK AB, BARTLETT JG, LOUIE T et al.: Microbial synergy in experimental intra-abdominal abscess. Infect. Immun. (1976) 13:22-26.
44. SAWYER RG, ROSENLOF LK, ADAMS RB et al.: Peritonitis into the 1990s: changing pathogens and changing strategies in the critically ill. Am. Surg. (1992) 58:82-87.
45. MONTRAVERS P, CHALFINE A, GAUSIT R et al.: Clinical and therapeutic features of non-postoperative nosocomial intra-abdominal infections. Ann. Surg. (2004) 239(3):409-416.
46. KOLLEF M: Appropriate empirical antimicrobial therapy for nosocomial infections: getting it right the first time. Drugs (2003) 63:2157-2168.
47. IBRAHIM EH, SHERMAN G, WARD S et al.: The influence of inadequate antimicrobial treatment of bloodstream infections on patients' outcomes in the ICU setting. Chest (2000) 118:146-155.
48. RELLO J, GALLEGO M, MARISCAL D et al.: The value of routine microbial investigation in ventilator-associated pneumonia. Am. J. Respir. Crit. Care Med. (1997) 156(1):196-200.
49. ALVAREZ-LERMA F: Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group. Intensive Care Med (1996) 22:387-394.
50. KOLEF MH, WARD S: The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia. Chest (1998) 113:412-420.
51. VALLES J, RELLO J, OCHAGAVIA A et al.: Community-acquired bloodstream infection in critically ill adult patients. Chest (2003) 123:1615-1624.
52. FALAGAS ME, BAREFOOT L, GRIFFITH J et al.: Risk factors leading to clinical failure in the treatment of intra-abdominal or skin/soft tissue infections. Eur. J. Clin. Microbiol. Infect. Dis. (1996) 15(12):913-921.
53. KROBOT K, YIN D, ZHANG Q et al.: Effect of inappropriate initial empiric antibiotic therapy on out come of patients with community-acquired intra-abdominal infections requiring surgery. Eur. J. Clin. Microbiol. Infect. Dis. (2004) 23(9):682-687.
54. BARE M, CASTELLS X GARCIA A et al.: Importance of appropriateness of empiric antibiotic therapy on clinical outcomes in intra-abdominal infections. Int. J. Technol. Assess. Health Care (2006) 22(2):242-248.
55. MEEHAN TP, FINE MJ, KRUMHOLZ HM et al.: Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA (1997) 278:2080-2084.
56. BARIE PS, HYDO LJ, SHOU J et al.: Influence of antibiotic therapy on mortality of critical surgical illness caused or complicated by infection. Surg. Infect. (2005) 6(1):41-54.
57. LUNA CM, VUJACICH P, NIEDERMAN MS et al.: Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Am. J. Respir. Crit. Care Med. (1997) 156:196-200.
58. PATERSON DL: 'Collateral damage' from cephalosporin or quinolone antibiotic therapy. Clin. Infect. Dis. (2004) 38(Suppl. 4):S341-S345.
59. ZERVOS MJ, HERSHBERGER E, NICOLAU DP et al.: Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991-2000. Clin. Infect. Dis. (2003) 37:1643-1648.
60. ENGLISH WP, WILLIAMS MD: Should aminoglycoside antibiotics be abandoned? Am. J. Surg. (2000) 180:512-516.
61. PAUL M, BENURI-SILBIGER I, SOARES-WEISER K et al.: β-lactam monotherapy versus β-lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomized trials. Br. Med. J. (2004) 328(7441):668.
62. PAUL M, SOARES-WEISER K, LEIBOVICHI L: β-lactam monotherapy versus β-lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. Br. Med. J. (2003) 326(7399):1111.
63. WONG PF, GILLIAM AD, KUMAR S et al.: Antibiotic regimens for secondary peritonitis of gastrointestinal origin in adults. Cochrane Database Syst. Rev. (2005) 18(2):CD004539.
64. BARIE PS, ROTSTEIN OD, DELLINGER EP et al.: The cost-effectiveness of cefepime plus metronidazole versus imipenem-cilastatin in the treatment of complicated intra-abdominal infection. Surg. Infect. (2004) 5(3):269-280.
65. DAVEY P, BROWN E, FENELON L, FINCH R et al.: Systematic review of antimicrobial drug prescribing in hospitals. Emerg. Infect. Dis. (2006) 12(2):211-216.
66. MOSDELL DM, MORRIS DM, VOLTURA A et al.: Antibiotic treatment for surgical peritonitis. Ann. Surg. (1991) 214:543-549.
67. MONTAVERS P, GAUZIT R, MULLER C et al.: Emergence of antibiotic-resistant bacteria in cases of peritonitis after intra-abdominal surgery affects the efficacy of empirical antimicrobial therapy. Clin. Infect. Dis. (1996) 23:486-494.
68. JONES RN, PFALLER MA: Bacterial resistance: a worldwide problem. Diagn. Microbiol. Infect. Dis. (1998) 31:379-388.
69. National Nosocomial Infections Surveillance (NNIS) System Report: data summary from January 1992 through June 2003, issued August 2003. Am. J. Infect. Control. (2003) 31:481-498.
70. LUCAS GM, LECHTZIN N, PURYEAR DW et al.: Vancomycin-resistant and vancomycin-susceptible enterococcal bacteremia: comparison of the clinical features and outcomes. Clin. Infect. Dis. (1998) 26:1127-1133.
71. BHAVNANI SM, DRAKE JA, FORREST A et al.: A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia. Diagn. Microbiol. Infect. Dis. (2000) 36:145-158.
72. LODISE TP, MCKINNON PS, TAM VH, RYBAK MJ: Clinical outcomes for patients with bacteremia caused by vancomycin resistant enterococcus in a level I trauma center. Clin. Infect. Dis. (2002) 34:922-929.
73. VERGIS EN, HAYDEN MK, CHOW JW et al.: Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia. A prospective multicenter study. Ann. Intern. Med. (2001) 135:484-492.
74. CARMELI Y, ELIOPOULOS G, MOZAFFARI E, SAMORE M: Health and economic outcomes of vancomycin-resistant enterococci. Arch. Intern. Med. (2002) 162:2223-2228.
75. KNOTHE H, SHAH P, KREMERY V et al.: Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection (1983) 11:315-317.
76. PALUCHA A, MILIKIEWITZ B, HRYNIEWITZ et al.: Concurrent outbreaks of extended-spectrum β-lactamase-producing organisms of the family Enterobacteriaceae in a Warsaw hospital. J. Antimicrob. Chemother. (1999) 44(4):489-499.
77. JONES RN, PFALLER MA, DOERN GV et al.: Antimicrobial activity and spectrum investigation of eight broad-spectrum β-lactam drugs: a 1997 surveillance trial in 102 medical centers in the United States. Diagn. Microbiol. Infect. Dis. (1998) 30:215-228.
78. ITOKAZU GS, QUINN JP, BELL-DIXON C et al.: Antimicrobial resistance rates among Gram-negative bacilli recovered from patients in intensive care units: evaluation of a national post marketing surveillance program. Clin. Infect. Dis. (1996) 23:779-784.
79. FRIDKIN SK, STEWARD CD, EDWARDS JR et al.: Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals. Project ICARE: Phase II. Clin. Infect. Dis. (1999) 29:245-252.
80. MATHAI D, JONES JN, STILWELL M, PFALLER MA: Three-year analysis of pathogen occurrence and antimicrobial resistance in 315 intensive care units within 71 participating medical centers (32 nations). Report from SENTRY antimicrobial surveillance program (1997-99). Presented in part in the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada (17 - 20 September 2000) Abstr. poster 1027.
81. HANBERGER H, DJEKEMA D, FLUIT A et al.: Surveillance of antibiotic resistance in European ICUs. J. Hosp. Infect. (2001) 48:161-176.
82. CHOW JW, SATISHCHANDRAN V, SNYDER TA et al.: In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2002 Study for Monitoring Antimicrobial Resistance Trends (SMART). Surg. Infect. (2005) 6:439-48.
83. DERYKE AC, MAGLIO D, NICOLAU DP: Defining the need for new antimicrobials: clinical and economic implications of resistance in the hospitalized patient. Expert Opin. Pharmacother. (2005) 6(6):873-889.
84. PATERSON DL: Resistance in Gram-negative bacteria: enterobacteriaccae. Am. J. Med. (2006) 119(6 Suppl. 1):S20-S28, discussion S62-S70.
85. GO ES, URBAN C, BURNS J et al.: Clinical and molecular epidemiology of Acinerobacter infections sensitive only to polymyxin B and sulbactam. Lancet (1994) 344:1329-1332.
86. RAHAL JJ, URBAN C, HORN D et al.: Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA (1998) 280:1233-1237.
87. LAUTENBACH E, PATEL JB, BILKER WB et al.: Extended-spectrum β-lactamase producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistant on outcomes. Clin. Infect. Dis. (2001) 32:1162-1171.
88. PATERSON DL, KO WC, VON GOTTBERG A et al.: Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum β-lactamases. Clin. Infect. Dis. (2004) 39:31-37.
89. KANG CI, KIM SH, PARK WB et al.: Bloodstream infections due to extended-spectrum β-lactamase producing Ercherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob. Agents Chemother. (2004) 48:4574-4581.
90. JONES RN, DESHPANDE LM, BELL JM et al.: Evaluation of the contemporary occurrence rates of metallo-β-lactamascs in multidrug-resistant Gram-negative bacilli in Japan: report from the SENTRY Antimicrobial Surveillance Program (1998-2002). Diagn. Microbiol. Infect. Dis. (2004) 49(4):289-294.
91. KANG CI, KIM SH, PARK WB et al.: Bloodstream infections caused by Enterobacter species: predictors of 30-day mortality rate and impact of broad-spectrum cephalosporin resistance on outcome. Clin. Infect. Dis. (2004) 39:812-818.
92. COSGROVE SE, KAYE KS, ELIOPOULOS GM, CARMELI Y: Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species. Arch. Intern. Med. (2002) 162:185-190.
93. KANG CI, KIM SH, KIM HB et al.: Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin. Infect. Dis. (2003) 37:745-751.
94. NEUHAUSER MM, WEINSTEIN RA, RYDMAN R et al.: Antibiotic resistance among Gram-negative bacilli in US intensive care units: implications for fluoroquinolones use. JAMA (2003) 289:885-888.
95. CARMELI Y, TROILLET N, KASHMER AW, SAMORE MH: Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch. Intern. Med (1999) 159:1127-1132.
96. CHAMBERS HF: Anti-infective therapy: Other β-lactam, antibiotics. In: Principles and Practice of Infectious Diseases, 6th edn. Mandell GL. Bennett JE, Dolin R. Elsevier Churchill Livingstone (2005) 21:311-318.
97. PERKERSON KA, KUTI JL, NICOLAU DP: Clinical pharmacokinetics of carbapenems. Antibiotics for Clinicians (2003) 7(Suppl. 2):24-29.
98. TAMPLER S, OCHS MM, HANCOCK REW: Role of the novel OprD family of porms in nutrient uptake in Pseudomonas aeruginosa. J. Bacteriol. (2006) 188(1):45-54.
99. BONFIGLIO G, RUSSO G, NICOLETTI G: Recent developments in carbapenems. Expert Opin. Invest. Drugs (2002) 11:529-544.
100. BUSH K: New β-lactamases in Gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy. Clin. Infect. Dis. (2001) 32:1085-1089.
101. YIGIT H, QUEENAN AM, ANDERSON GJ et al.: Novel carbapenem-hydrolyzing β-lactamase, KPC-1, from a carbapenem resistant strain of Klebsiella pneumoniae. Antimicrob. Agents Chemother. (2001) 45:1151-1161.
102. YIGIT H, ANDERSON GJ, BIDDLE JW et al.: Carbapenem resistance in a clinical isolate of Enterobacter acrogenes is associated with decreased expression of OmpF and OmpC porin analogs. Antimicrob. Agents Chemother (2002) 46:3817-3822.
103. KOHLER T, MICHEA-HAMZEHPOUR M, EPP SF et al.: Carbapenem activities against Pseudomonas aeruginosa: respective contributions of OprD and efflux systems. Antimicrob. Agents Chemother. (1999) 43:424-427.
104. BALLESTERO S et al.: Carbapenem resistance in Pseudomonas aeruginosa from cystic fibrosis patients. J. Antimicrob. Chemother. (1996) 38:39-45.
105. LI XZ, ZHANG L, POOLE K: Interplay between the MexA-MexB-OprM multi-drug efflux system and the outer membrane barrier in the multiple antibiotic resistance of Pseudomonas aeruginosa. J. Antimicrob. Chemother. (2000) 45:433-436.
106. BORNET C et al.: Imipenem and expression of multi drug efflux pump in Enterobacter acrogenes. Biochem. Biophys. Res. Commun. (2003) 301:985-990.
107. LIVERMORE DM: Of Pseudomonas, porins, pumps and carbapenems. J. Antimicrob. Chemother. (2001) 47:247-250.
108. SENTOCHNIK DE, ELIOPOULOUS GM, FERRARO MJ, MOLLERING RC Jr: Comparative in vitro activity of SM7338, a new carbapenem, antimicrobial agent. Antimicrob. Agents Chemother. (1989) 33:1232-1236.
109. EDWARDS JR, TURNER PJ, WANNOP C, WITHNELL ES, GRINDEY AJ, NAIRN K: In vitro antibacterial activity of SM7338, a carbapenem antibiotic with stability to dehydropeptidase I. Antimicrob. Agents Chemother. (1989) 33:215-222.
110. JONES RN: Review of the in vitro spectrum of activity of imipenem. Am. J. Med. (1985) 78:22-32.
111. IACONNIS JP, PTKIN DH, SHEIKH W, NADLER HL: Comparison of antibacterial activities of meropenem and six other antimicrobials against Pseudomonas aeruginosa isolates from North America studies and clinical trials. Clin. Infect. Dis. (1997) 24(Suppl. 2):S191-S196.
112. FUCHS PC, BARRY AL, BROWN SD: In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American centers. Antimicrob. Agents Chemother. (2001) 45:1915-1918.
113. LIVERMORE DM, CARTER MW, BAGEL S et al.: In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia. Antimicrob. Agents Chemother. (2001) 45:1860-1867.
114. GOOSSENS H: MYSTIC (Meropenem Yearly Susceptibility test Information Collection) results from Europe: comparison of antibiotic susceptibilities between countries and centre types. J. Antimicrob. Chemother (2000) 46(Suppl. B):39-52.
115. GOOSSENS H: Susceptibility of multi-drug resistant Pseudomonas aeruginosa in intensive care units: results from European MYSTIC study group. Clin. Microbiol. Infect. (2003) 9(9):980-983.
116. UNAL S, GARCIA-RODRIGUEZ JA: Activity of meropenem and comparators against Pseudomonas acruginosa and Acinetobacter spp. isolated in the MYSTIC Program, 2002-2004. Diagn. Microbiol. Infect. Dis. (2005) 53(4):265-271.
117. GOFF DA, MANGINO J: Ertapenem: effect on Gram-negative pathogens 7 months after formulary addition. Presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA (30 October - 2 November 2004) Abstr. K-343:322.
118. LIVERMORE DM, MUSHTAG S, WARNER M: Selectivity of ertapenem for Pseudomonas aeruginosa mutants cross-resistant to other carbapenems. J. Antimicrob. Chemother. (2005) 55:306-311.
119. KOHLER J, YOUNG K, PAINTER RE et al: Ertapenem resistance selection in Pseudomonas aeruginosa. Presented at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA (16 - 19 December 2001) Abstr. 1518.
120. DRUSANO GL, HUTCHINSON M: The pharmacokinetics of meropenem. Stand. J. Infect. Dis. Suppl. (1995) 96:11-16.
121. MOUTON JW, VAN DER ANKER JN: Meropenem clinical pharmacokinetics. Clin. Pharmacokinet. (1995) 28(4):275-286.
122. BAX RP, BASTAIN W, FEATHERSTONE A et al.: The pharmacokinetics of meropenem, in volunteers. J. Antimicrob. Chemother. (1989) 24(Suppl. A):311-320.
123. LEROY A, FILLASTRE JP, BORSA-LEBAS F et al.: Pharmacokinetics of meropenem (ICI-194,660) and its metabolite (IC10-213,689) in healthy subjects and in patients with renal impairment. Antimicrob. Agents Chemother. (1992) 36:2794-2798.
124. BEDIKIAN A, OKAMOTO MP, NAKAHIR0 RK et al.: Phermacokinetics of meropenem in patients with intra-abdominal infection. Antimicrob. Agents Chemother. (1994) 38(1):151-154.
125. WISE R, DONOVAN IA, LOCKLEY MR et al.: The pharmacokinetics and tissue penetration of imipenem. J. Antimicrob. Chemother. (1986) 18(Suppl. E):93-101.
126. DRUSANO GL, STANDIFORD HC: Pharmacokinetic profile of imipenem/ cilastatin in normal volunteers. Am. J. Med. (1985) 78:47-53.
127. DRUSANO GL: An overview of the pharmacology of imipenem/cilastatin. J. Antimicrob. Chemother. (1986) 18(Suppl. E):79-92.
128. PLETZ MWR, RAU M, BULITA J et al.: Ertapenem pharmacokinetics and impact on intestinal microflora, in comparison to those of ceftriaxone, after multiple dosing in mate and female volunteers. Antimicrob. Agents Chemother. (2004) 48(10):3765-3772.
129. MOUTON JW, TOUW DJ, HORREVORTS AM, VINKS AA: Comparative pharmacokinetics of the carbapenems. Clin. Pharmacokinet. (2000) 39(3):185-201.
130. MAJUMDAR AK, MUSSON DG, BIRK KL et al.: Pharmacokinetics of ertapenem in healthy young volunteers. Antimicrob. Agents Chemother. (2002) 46:3506-3511.
131. DONELLY JP, HORREVORTS AM, SAUERNWIN RW et al.: High dose meropenem in meningitis due to Pseudomonas aeruginosa [letter]. Lancet (1992) 1:1117.
132. CAPITANO B, NICOLAU DP, POTOSKI BA et al.: Meropenem administered as a prolonged infusion to treat serious Gram-negative central nervous system infections. Pharmacotherapy (2004) 24(6):803-807.
133. COTTAGNOUD P, PFISTER M, COTTAGNOUD M et al.: Activities of ertapenem, a new long-acting carbapenem, against penicillin-sensitive or penicillin-resistant pneumococci in experimental meningitis. Antimicrob. Agents Chemother. (2003) 47:1943-1947.
134. BALFOUR JA, BRYSON HM, BROGDEN RN: Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections. Drug (1996) 51:99-136.
135. KOPPEL BS, HAUSER WA, POLITIS C et al.: Seizures in the critically ill: the role of imipenem. Epilepsia (2001) 42:1590-1593.
136. NORRBY SR, GILDON KM: Safety profile of meropenem: a review of nearly 5,000 patients treated with meropenem. Scand J. Infect. Dis. (1999) 31(1):3-10.
137. SETO AH, SONG JC, GUEST SS: Ertapenem-associated seizures in a peritoneal dialysis patient. Ann. Pharmacother. (2005) 39(2):352-356.
138. SOLOMKIN JS, FANT WK, RIVERA JO, ALEXANDER JW: Randomized trial of imipenem/cilastatin versus gentamicin and clindamycin in mixed flora infections. Am. J. Med. (1985) 78(6A):85-91.
139. LEAPER DJ, KENNEDY RH, SUTTON A et al.: Treatment of acute bacterial peritonitis: a trial of imipenem/cilastatin against ampicillin-metronidazole-gentamicin. Scand J. Infect. Dis. Suppl. (1987) 52:7-10.
140. GONZENBACH HR, SIMMEN HP, AMGWERD R: Imipenem (N-F-thienamycin) versus netilmicin plus clindamycin. A controlled and randomized comparison in intra-abdominal infections. Ann. Surg. (1987) 205(3):271-275.
141. SOLOMKIN JS, DELLINGER EP, CHRISTOU NV, BUSUTTIL RW: Results of a multicenter trial comparing imipenem/cilastatin to tobramycin/ clindamycin for intra-abdominal infections. Ann. Surg. (1990) 212(5):581-591.
142. ECKHAUSER FE, KNOL JA, RAPER SE et al.: Efficacy of two comparative antibiotic regimens in the treatment of serious intra-abdominal infections: results of a multicenter study. Clin. Ther. (1992) 14(1):97-109.
143. BRISMAR B, MALMBORG AS, TUNEVALL G et al.: Piperacillin/tazobactam versus imipenem-cilastatin for the treatment of intra-abdominal infections. Antimicrob. Agents Chemother. (1992) 36(12):2766-2773.
144. NIINIKOSKI J, HAVIA T, ALHAVA E et al.: Piperacillin/tazobactam versus imipenem/cilascatin in the treatment of intra-abdominal infections. Surg. Gynecol. Obstet. (1993) 176(3):255-261.
145. DE GROOT HG, HUSTINX PA, LAMPE AS, OOSTERWIJK WM: Comparison of imipenem/ cilastatin with the combination of aztreonam and clindamycin in the treatment of intra-abdominal infections. J. Antimicrob. Chemother. (1993) 32(3):491-500.
146. SOLOMKIN JS, REINHART HH, DELLINGER EP et al.: Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilascatin for intra-abdominal infections. The Intra-Abdominal Infection Study Group. Ann. Surg. (1996) 223(3):303-315.
147. ANGERAS MH, DARLE N, HAMNSTROM K et al.: A comparison of imipenem/ cilastatin with the combination of cefuroaxime and metronidazole in the treatment of intra-abdominal infections. Scand J. Infect. Dis. (1996) 28:513-518.
148. ERASMO AA, CRISOSTOMO AC, YAN LN et al.: Randomized comparison of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of patients with intra-abdominal infection. Asian J. Surg. (2004) 27(3):227-235.
149. OLIVA ME, REKHA A, YELLIN A et al.: A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744]. BMC Infect. Dis. (2005) 19(5):88.
150. VERWAEST C; BELGIAN MULTICENTER STUDY GROUP: Meropenem versus imipenem/ cilastatin as empirical monotherapy for serious bacterial infections in the intensive care unit. Clin. Microbiol. Infect. (2000) 6(6):294-302.
151. GARAU J, BLANQUER J, COBO L et al.: Prospective, randomized, multicenter study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections. Eur. J. Microbiol. Infect. Dis. (1997) 16(11):789-796.
152. ZANETTI G, HARBARTH SJ, TRAMPUZ A et al.: Meropenem (1.5g/day) is as effective as imipenem/cilastatin (2 g/day) for the treatment of moderately severe intra-abdominal infections. Int. J. Antimicrob. Agents (1999) 11(2):107-113.
153. BASOLI A, MELI EZ, MAZZOCCHI P, SPERANZA V: Imipenem/cilastatin (1.5 g/ day) versus meropenem (3.0 g/day) in patients with intra-abdominal infections: results of a prospective randomized, multicenter, trial. Scand J. Infect. Dis. (1997) 29(5):503-508.
154. BRISMAR B, MALMBORG AS, TUNEVALL G et al.: Meropenem versus imipenem/ cilastatin in the treatment of intra-abdominal infections. J. Antimicrob. Chemother. (1995) 35(1):139-148.
155. GEROULANOS SJ: Meropenem versus imipenem/cilastatin in intra-abdominal infections requiring surgery. J. Antimicrob. Chemother. (1995) 36(Suppl. A):191-205.
156. YELLIN AE, HASSETT JM, FERNANDEZ A et al.: Ertapenem monotherapy versus combination therapy with ceftriaxone plus metronidazole for the treatment of complicated intra-abdominal infections in adults. Int. J. Antimicrob. Agents (2002) 20(3):165-173.
157. TELLADO J, WOODS GL, GESSER R et al.: Ertapenem versus piperacillin-tazobactam for the treatment of mixed anaerobic complicated intra-abdominal, complicated skin and skin structure, and acute pelvic infections. Surg. Infect. (2002) 3(4):303-314.
158. TEPPLER H, MEIBOHM AR, WOODS GL: Management of complicated appendicitis and comparison of outcome with other primary sites of intra-abdominal infection: results of a trial comparing ertapenem and piperacillin-tazobactam. J. Chemother. (2004) 16(1):62-69.
159. DELA PENA AS, ASPERGER W, KOCKERLING F et al.: Efficacy and safety of ertapenem versus piperacillin-tazobactam for the treatment of intra-abdominal infections requiring surgical intervention. J. Gastrointest. Surg. (2006) 10(4):567-574.
160. HUIZINGA WK WARREN BL, BAKER LW et al.: Antibiotic monotherapy with meropenern in the surgical management of intra-abdominal infections. J. Antimicrob. Chemother. (1995) 36(Suppl. A): 179-189.
161. KEMPF P, BAUERNFEIND A, MULLER A et al.: Meropenem monotherapy versus cefotaxime plus metronidazole combination treatment for serious intra-abdominal infections. Infection (1996) 24(6):473-479.
162. WILSON SE: Results of a randomized, multicenter trial of meropenem versus clindamycin/tobramycin for the treatment of intra-abdominal infections. Clin. Infect. Dis. (1997) 24(Suppl. 2):S197-S206.
163. MEHTAR S, DEWAR EP, LEAPER DJ, TAYLOR EW: A multi-centre study to compare meropenem, and cefotaxime and metronidazole in the treatment of hospitalized patients with serious infections. J. Antimicrob. Chemother. (1997) 39(5):631-638.
164. BRISMAR B, AKERLUND JE, SJOSTEDT S et al.: Biapenem versus imipenem/ cilastatin in the treatment of complicated intra-abdominal infections: report from a Swedish Study Group. Scand J. Infect. Dis. (1996) 28(5):507-512.
165. SOLOMKIN JS, WILSON SE, CHRISTOU NV et al.: Results of a clinical trial of clinafloxacin versus imipenem/cilastatin for intra-abdominal infections. Ann. Surg. (2001) 233(1):79-87.
166. BABINCHAK T, ELLIS-GROSSE E, DARTOIS N et al.: The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin. Infect. Dis. (2005) 1(41)Suppl. 5:S354-S367.
167. SOLOMKIN JS, YELLIN AE, ROTSTEIN OD et al.: Ertapenem versus piperacillin/tazobactam in the treatment of complicated intra-abdominal infections: results of a double-blind, randomized comparative Phase III trial. Ann. Surg. (2003) 237(2):235-245.
168. JASPERS CA, KIEFT H, SPEELBERG B et al.: Meropenem versus cefuroxime plus gentamicin for treatment of serious infections in elderly patients. Antimicrob. Agents Chemother. (1998) 42(5):1233-1238.
169. PATERSON DL, ROSSI F, BAQUERO F et al.: In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART). J. Antimicrob. Chemother. (2005) 55(6):965-973.
170. KOTAPATI S, KUTI JL, NICOLAU DP: Pharmacodynamic modelling of β-lactam antibiotics for the empiric treatment of secondary peritonitis: a report from the OPTAMA program. Surg. Infect. (2005) 6(3):297-304.
171. EAGYE KJ, KUTI JL, NICOLAU DP: Pharmacodynamic comparison of the carbapenems against E. coli and Klebsiella spp. containing extended spectrum β-lacramases. Am J. Infect. Dis. (2005) 1:149-155.
172. LIAO CH, SHENG VM, WANG JT et al.: In vitro activities of 16 antimicrobial agents against clinical isolates of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in two regional hospitals in Taiwan. J. Antimicrob. Immunol. Infect. (2006) 39:59-66.
173. JACKSON JJ, KROPP H: β-lactam antibiotic-induced release of free endotoxin: in vitro comparison of penicillin-binding (PBP) 2-specific
174. BUCKLIN SE, FUJIHARA Y, LEESON MC, MORISON DC: Differential antibiotic induced release of endotoxin from Gram-negative bacteria. Eur. J. Clin, Microb. Infect. Dis. (1994) 13(Suppl. 1):43-51.
175. TRAUTMANN M, ZICK R, RUKAVINA T et al.: Antibiotic-induced release of endotoxin: in vitro comparison of meropenem and other antibiotics. J. Antimicrob. Chemother. (1998) 41:163-169.
176. BUCKLIN SE, MORISON DC: Differences in therapeutic efficacy among cell wall-active antibiotics in a mouse model of Gram-negative sepsis. J. Infect. Dis. (1995) 172:1519-1527.
177. JACKSON JJ, KROPP H: Carbapenem-and cephalosporin-induced release of lipopolysaccharide from smooth and rough Pseudomonas aeruginosa: in vitro relevance. In: Differential Release and Impact of Antibiotic-Induced Endotoxin. Faist E (Ed.) Merck, Whitehouse, NJ. (1995):21-35.
178. KEATING M, PERRY CM: Ertapenem: a review of its use in the treatment of bacterial infections. Drugs (2005) 65(15):2151-2178.
179. PELAC BA, WOODS GL, TEPPLER H et al.: Comparative in-vitro activities of ertapenem against aerobic bacterial pathogens isolated from patients with complicated intra-abdominal infections. J. Chemother. (2002) 14(3):227-233.